Atria Investments Inc Invests $148,000 in OmniAb, Inc. (NASDAQ:OABI)

Atria Investments Inc acquired a new stake in OmniAb, Inc. (NASDAQ:OABI) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 35,081 shares of the company’s stock, valued at approximately $148,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Rice Hall James & Associates LLC raised its stake in OmniAb by 6.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after acquiring an additional 163,038 shares during the period. Palumbo Wealth Management LLC raised its stake in OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after acquiring an additional 2,744 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in OmniAb by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after acquiring an additional 8,909 shares during the period. CWC Advisors LLC. bought a new stake in OmniAb in the 3rd quarter valued at about $54,000. Finally, Woodstock Corp raised its stake in OmniAb by 5.6% in the 3rd quarter. Woodstock Corp now owns 792,853 shares of the company’s stock valued at $3,354,000 after acquiring an additional 42,310 shares during the period. 72.08% of the stock is currently owned by institutional investors.

OmniAb Trading Up 1.8 %

Shares of NASDAQ OABI opened at $3.92 on Monday. OmniAb, Inc. has a 12 month low of $3.56 and a 12 month high of $6.72. The firm has a market capitalization of $553.58 million, a price-to-earnings ratio of -6.32 and a beta of -0.12. The business has a 50-day moving average of $4.14 and a 200-day moving average of $4.24.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 target price on shares of OmniAb in a report on Friday, August 16th. Benchmark reaffirmed a “buy” rating and set a $8.00 target price on shares of OmniAb in a report on Thursday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.